Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

Jorg Oddens, Maurizio Brausi, Richard Sylvester, Aldo Bono, Cees van de Beek, George van Andel, Paolo Gontero, Wolfgang Hoeltl, Levent Turkeri, Sandrine Marreaud, Sandra Collette, Willem Oosterlinck

Research output: Contribution to journalArticleAcademicpeer-review

119 Citations (Scopus)
Original languageEnglish
Pages (from-to)462-472
JournalEuropean Urology
Issue number3
Publication statusPublished - Mar 2013


  • Non-muscle invasive bladder cancer
  • Randomized Controlled Trial
  • Immunotherapy
  • Bacillus Calmette-Guerin
  • Adjuvant treatment
  • Urinary bladder
  • Maintenance therapy

Cite this